Vedolizumab‐Associated Primary Cutaneous CD4 + Small/Medium T‐Cell Lymphoproliferative Disorder in a Biologic‐Naïve Pediatric Patient With Crohn's Disease
Abstract
Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (PCSM-TCLPD) is a rare lymphoproliferative disorder that is occasionally diagnosed in children and adolescents. We present a case of PCSM-TCLPD in an 11-year-old female with biologic-naïve Crohn's disease well-controlled on vedolizumab, which was initiated 12 months prior to lesion appearance. We propose that vedolizumab may have played a role in the development of PCSM-TCLPD.
Fields of Study & Subjects
Cutaneous lymphoproliferative disorders research
Viral-associated cancers and disorders
Lymphoma Diagnosis and Treatment
Publication details
- Journal / source
- Pediatric Dermatology
- Publisher
- Wiley
- Volume
- 43
- Issue
- 3
- Pages
- 781–782
- Publication date
- 20 February 2026
- Language
- EN